On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 4 Article 3
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 4, 24 January 2008
Rapid communications
European Centre for Disease Prevention and Control issues guidance for the introduction of human papillomavirus (HPV) vaccines in European Union countries
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Hamers FF. European Centre for Disease Prevention and Control issues guidance for the introduction of human papillomavirus (HPV) vaccines in European Union countries. Euro Surveill. 2008;13(4):pii=8022. Available online:


Two prophylactic human papillomavirus (HPV) vaccines have been licensed in Europe: the quadrivalent vaccine, Gardasil® (Sanofi Pasteur MSD) and the bivalent vaccine, Cervarix® (GlaxoSmithKline Biologicals) [1,2]. Both vaccines are made from virus-like particles and are non-infectious [3]. Both vaccines protect against the high-risk HPV types 16 and 18, which cause an estimated 73% of cervical cancer cases in Europe. Gardasil also protects against HPV 6 and 11, which cause most cases of genital warts. Both vaccines have a good safety profile. They have been shown to prevent more than 90% of precancerous lesions associated with types 16 or 18 among HPV naïve women in clinical trials [4].

Cervical cancer is the second most common cancer after breast cancer among women aged 15-44 years in the European Union (EU). Each year, there are around 33,000 cases of cervical cancer in the EU, and 15,000 deaths [5]. Persistent infection of the genital tract by a high-risk HPV type is a necessary, although not sufficient cause of cervical cancer [6]. Genital HPV infections are very common and are usually acquired soon after onset of sexual activity [7]. Most of these infections are clinically asymptomatic and spontaneously cleared. However, persistent HPV infections with a high-risk HPV type can cause cellular changes of the cervix that can progress to cervical cancer. High-risk HPV types are also associated with other ano-genital cancers, and some head and neck cancers in both men and women. Some other HPV types (referred to as low-risk) cause genital warts in both men and women.

The European Centre for Disease Prevention and Control (ECDC) has issued "Guidance for the Introduction of HPV Vaccines in EU countries" on 22 January 2008, at the request of the European Commission and several of the EU Member States [8]. Coordinated by ECDC, a scientific panel of independent experts* was set up to analyse scientific evidence for the introduction of HPV vaccines and list the policy options available to the Member States. The guidance document highlights the issues to be considered and lays down a scientific basis to support policy decisions across the EU.

HPV vaccines are becoming introduced in an increasing number of countries and EU policymakers are urged to consider HPV vaccination [9]. This guidance note should help facilitate this process. The target audiences for the guidance are national immunisation programme managers, policymakers at EU and national level, and experts involved in the decision making process on introduction of HPV vaccines.

To date, there is only about five-year follow-up data from the HPV vaccine studies and many questions remain to be answered in addition to duration of protection. This guidance note, made on the basis of current knowledge will probably need to be reviewed in 6 to 12 months.

HPV vaccines and cervical cancer screening
Well organised cervical cancer screening programmes are proven to reduce cervical cancer incidence by as much as 80-90% in women attending for screening [10]. HPV vaccine offers a complementary tool to improve the control of cervical cancer but does not eliminate the need for cervical cancer screening. Women need to be informed and motivated to attend screening programmes, even if they are vaccinated against HPV 16 and 18. One of the most important challenges will be to achieve integrated vaccination and screening strategies in a cost-effective way with the maximum benefit for women.

Who should be vaccinated?
The primary target group for routine vaccination is young adolescent girls before they become sexually active. Targeting older girls and young women with catch-up vaccination could increase vaccination benefits in the short term. Country-specific factors are important to determine the exact age for routine vaccination, and the ages for any catch-up vaccination.

Strategy options for HPV vaccine delivery in EU countries
School-based immunisation is likely to be the lowest cost option for delivery of HPV vaccines to pre-adolescent girls. However, local issues, such as whether there are school-based health services, funding arrangements for vaccine purchase and administration, and obtaining parental consent may affect the feasibility of this approach. Clinic or practice-based immunisation is a universally available additional or alternative option for HPV vaccine delivery. Sexual and reproductive health and other medical clinics provided specifically for women may be important sites for immunisation.

Modelling costs and outcomes of HPV vaccination
HPV vaccination should be evaluated not only for its effectiveness, but also from an economic point of view. Studies undertaken in a number of countries seem to indicate that HPV vaccination of pre-adolescent girls has a favourable cost-effectiveness profile. Economic evaluations are, however, not entirely exportable, due to the variability of costs and healthcare systems in different countries. Therefore, efforts should be made by each country to perform economic evaluation, taking into account existing cervical cancer prevention programmes, before taking a decision on the best strategy to prevent cervical cancer.

Monitoring and evaluating the impact of HPV vaccination
Post-licensure evaluation of the HPV vaccines will need to determine vaccination uptake and compliance, long-term efficacy and effectiveness of the vaccines, vaccine safety and herd immunity. Coordination between vaccine monitoring and cancer control programmes will be critical to assess the impact of the vaccine and its benefits compared with other existing prevention interventions such as screening. The minimum set of information to monitor HPV vaccination should include data on vaccine coverage, monitoring of adverse events following immunisation and surveillance of impact on pre-cancer lesions.

*The scientific panel was coordinated by Françoise Hamers and Pierluigi Lopalco from the Scientific Advice Unit at ECDC. It was chaired by Patricia Clayes (University of Ghent, Belgium) and included five other members: Ahti Anttila (Finnish Cancer Registry, Finland), Paolo Bonani (University of Florence, Italy), Adam Finn (Institute of Child Life and Health, UK), Daniel Lévy-Bruhl (Institut de veille sanitaire, France), and Kate Soldan (Health Protection Agency, UK).



  1. European Commission. Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 September 2006 to 30 September 2006. Official Journal of the European Union, 27 October 2006. Available from:
  2. European Commission. Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 September 2007 to 30 September 2007. Official Journal of the European Union, 26 October 2007. Available from:
  3. Cutts FT, Franceschi S, Goldie S, Castellsagué X, de Sanjose S, Garnett G, et al. Human Papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization 2007; 85: 719-726.
  4. Howell-Jones R. Human papillomavirus vaccination: the United Kingdom’s recommendation and update on European licensure and efficacy data. Available from:
  5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 version 2.0. IARC press, Lyon 2004.
  6. Bosch FX, Lorinez A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
  7. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24S3: S3/52-S3/61.
  8. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. Stockholm, ECDC, January 2008. Available at:
  9. Kudjawu Y, Lévy-Bruhl D, Pastore Celentano L, O’Flanagan D, Salmaso S, Lopalco P, et al. The current status of HPV and rotavirus vaccines in national immunisation schedules in the EU – preliminary results of a VENICE survey. Euro Surveill. 2007;12(4):E070426.1. Available from:
  10. International Agency for Research on Cancer Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J. 1986;293:659-664.


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.